Company Filing History:
Years Active: 2011-2012
Title: Igor Ivanov: Innovator in Cancer Treatment
Introduction
Igor Ivanov is a notable inventor based in Markt Indersdorf, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. With a total of 2 patents, Ivanov's work focuses on inhibitors that target specific kinases involved in tumor proliferation.
Latest Patents
Ivanov's latest patents include groundbreaking inventions aimed at combating cancer. One of his patents involves Raf inhibitors, which provide derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds serve as inhibitors of kinases such as Raf and demonstrate anti-proliferative activity against tumor cells, making them valuable in the treatment of various cancers. Another significant patent describes an anti-proliferative combination therapy that utilizes certain platinum-based chemotherapeutic agents alongside EGFR inhibitors or pyrimidine analogues. This invention outlines methods and compositions for the prevention and treatment of cancers, particularly through combination therapies.
Career Highlights
Throughout his career, Igor Ivanov has worked with prominent companies in the pharmaceutical industry. He has been associated with Agennix AG and Forma Therapeutics, Inc., where he has contributed to the development of innovative cancer therapies. His expertise in the field has positioned him as a key player in advancing cancer treatment options.
Collaborations
Ivanov has collaborated with several professionals in his field, including Katja Wosikowski-Buters and Christoph Schaab. These collaborations have further enhanced his research and development efforts, leading to significant advancements in cancer therapies.
Conclusion
Igor Ivanov's contributions to cancer treatment through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work continues to influence the pharmaceutical landscape, paving the way for new therapeutic approaches.